
Exact Sciences (EXAS) is anticipated to report strong results for its upcoming quarter, with consensus estimates projecting a 147.6% year-over-year EPS increase to $0.10 and 14.3% revenue growth to $809.93 million. The company demonstrates a high probability of exceeding these consensus estimates, driven by a positive Zacks Earnings ESP of +56.25% and a Zacks Rank #1, positioning it as a compelling earnings-beat candidate for institutional investors.
Exact Sciences (EXAS) is anticipated to report robust results for the quarter ended September 2025, with consensus estimates projecting a significant year-over-year EPS increase of 147.6% to $0.10 per share and revenue growth of 14.3% to $809.93 million. Analyst sentiment has been increasingly bullish, evidenced by a 9.76% upward revision in the consensus EPS estimate over the past 30 days, suggesting improving business conditions and heightened confidence among covering analysts. The company exhibits a high probability of exceeding these consensus estimates, supported by a strong Zacks Earnings ESP of +56.25% and a Zacks Rank #1 (Strong Buy). This combination historically predicts an earnings beat nearly 70% of the time, indicating that the Most Accurate Estimate is significantly higher than the consensus. Furthermore, Exact Sciences has a strong track record, having surpassed EPS estimates in three of the last four quarters, including a substantial 1,200% surprise in the previous quarter. This strong earnings outlook, coupled with positive analyst revisions and a high probability of an earnings beat, positions EXAS as a compelling candidate for potential positive stock price movement post-announcement on November 3. While an earnings beat does not guarantee stock appreciation, the confluence of these positive indicators suggests favorable investor sentiment leading into the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment